AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%
Last update at 2024-04-22T20:02:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -532.78400M | -457.89200M | 606.07M | -680.23800M | -372.88200M |
| Minority interest | - | - | - | - | - |
| Net income | -503.26700M | -450.82700M | 606.07M | -650.15100M | -372.88200M |
| Selling general administrative | 227.70M | 183.50M | 196.95M | 345.78M | 201.40M |
| Selling and marketing expenses | - | - | - | - | 44.60M |
| Gross profit | 6.87M | 5.75M | 1113.63M | 6.47M | 90.27M |
| Reconciled depreciation | 1.12M | 4.18M | 2.63M | 2.28M | 1.14M |
| Ebit | -548.11100M | -465.09100M | 596.23M | -710.40700M | -394.38100M |
| Ebitda | -546.98900M | -460.90900M | 651.71M | -708.12400M | -393.23800M |
| Depreciation and amortization | 1.12M | 4.18M | 55.49M | 2.28M | 1.14M |
| Non operating income net other | 0.01M | 0.13M | 0.25M | 0.08M | 0.02M |
| Operating income | -546.98900M | -460.90900M | 596.23M | -708.12400M | -393.23800M |
| Other operating expenses | 554.67M | 467.22M | 490.23M | 714.99M | 483.51M |
| Interest expense | 14.19M | 7.20M | 0.00000M | 0.00000M | 0.00000M |
| Tax provision | - | - | - | - | - |
| Interest income | 14.19M | 2.88M | 9.60M | 27.80M | 20.33M |
| Net interest income | 14.19M | 2.88M | 9.60M | 27.80M | 20.33M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | 27.74M | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -29.51700M | -7.06500M | 15.52M | -30.08700M | 20.36M |
| Total revenue | 7.69M | 6.31M | 1114.20M | 6.87M | 90.27M |
| Total operating expenses | 553.86M | 466.66M | 489.67M | 714.59M | 483.51M |
| Cost of revenue | 0.81M | 0.55M | 0.56M | 0.40M | 282.11M |
| Total other income expense net | 14.21M | 3.02M | 9.85M | 27.89M | 0.02M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -532.78400M | -457.89200M | 606.07M | -680.23800M | -372.88200M |
| Net income applicable to common shares | -532.78400M | -457.89200M | 606.07M | -680.23800M | -372.88200M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1356.45M | 1825.29M | 2159.25M | 1084.15M | 952.71M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 50.83M | 58.35M | 22.82M | 26.70M | 21.92M |
| Total liab | 103.85M | 96.26M | 86.91M | 139.50M | 89.73M |
| Total stockholder equity | 1252.60M | 1729.03M | 2072.33M | 944.65M | 862.97M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 72.67M | 67.28M | 54.85M | 86.62M | 51.99M |
| Common stock | 0.00600M | 0.00600M | 0.00600M | 0.00500M | 0.00500M |
| Capital stock | 0.00600M | 0.00600M | 0.00600M | 0.00500M | 0.00500M |
| Retained earnings | -2028.17000M | -1495.38600M | -1037.49400M | -1643.56700M | -963.32900M |
| Other liab | 0.10M | 0.10M | 0.27M | 0.52M | 3.70M |
| Good will | - | - | - | - | - |
| Other assets | 6.04M | 5.52M | 5.06M | 6.16M | 2.37M |
| Cash | 162.70M | 294.23M | 1661.08M | 126.70M | 190.94M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 99.26M | 85.19M | 67.20M | 112.13M | 86.03M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -150.56600M | -275.80100M | -1632.98200M | -89.61300M | -190.94300M |
| Short term debt | 7.64M | 7.47M | 8.66M | 10.24M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 12.13M | 18.43M | 28.10M | 37.09M | - |
| Other stockholder equity | 3290.97M | 3227.07M | 3109.41M | 2586.92M | 1826.81M |
| Property plant equipment | 2.90M | 19.12M | 6.75M | 9.13M | 5.64M |
| Total current assets | 1272.49M | 1800.64M | 2122.37M | 1035.09M | 944.70M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 1252.60M | 1729.03M | 2072.33M | 944.65M | 862.97M |
| Short term investments | 1109.79M | 1448.06M | 438.47M | 881.69M | 731.83M |
| Net receivables | 13.66M | 18.51M | - | - | - |
| Long term debt | - | - | - | - | - |
| Inventory | -64.48600M | -18.50600M | - | - | - |
| Accounts payable | 18.95M | 10.45M | 3.69M | 15.27M | 34.04M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -10.20600M | -2.66000M | 0.41M | 1.29M | -0.51500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.00600M | 0.00600M | 0.00600M | 0.00500M | 0.00500M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -2028.17000M | -1495.38600M | -1037.49400M | -1643.56700M | -963.32900M |
| Treasury stock | - | - | - | -0.40000M | -0.21100M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 70.53M | 5.52M | 5.06M | 6.16M | 2.37M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 83.95M | 24.64M | 36.88M | 49.06M | 8.01M |
| Capital lease obligations | 12.13M | 18.43M | 28.10M | 37.09M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 326.37M | -1002.07600M | 443.03M | -137.40500M | -509.60100M |
| Change to liabilities | 13.05M | 6.69M | -43.66800M | 15.02M | 34.67M |
| Total cashflows from investing activities | 325.43M | -1002.44800M | 442.68M | -143.15600M | -512.46100M |
| Net borrowings | - | - | - | -0.32800M | -0.34000M |
| Total cash from financing activities | 3.07M | 13.33M | 426.76M | 607.62M | 659.36M |
| Change to operating activities | -2.76200M | -25.19500M | -28.21800M | 25.44M | -5.33200M |
| Net income | -532.78400M | -457.89200M | 606.07M | -680.23800M | -372.88200M |
| Change in cash | -131.53300M | -1367.29600M | 1533.73M | -64.23800M | -113.77400M |
| Begin period cash flow | 295.50M | 1662.80M | 129.07M | 193.31M | 307.08M |
| End period cash flow | 163.97M | 295.50M | 1662.80M | 129.07M | 193.31M |
| Total cash from operating activities | -460.03600M | -378.18200M | 664.28M | -528.70600M | -260.67100M |
| Issuance of capital stock | 0.00000M | 0.00000M | 417.50M | 561.28M | 631.49M |
| Depreciation | 1.12M | 4.18M | 2.63M | 2.28M | 1.14M |
| Other cashflows from investing activities | - | - | - | -137.40500M | -509.60100M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | 3.11M | 14.72M | 9.26M | 610.13M | 660.60M |
| Other cashflows from financing activities | 3.07M | 13.33M | 9.26M | 46.35M | 27.86M |
| Change to netincome | 60.10M | 94.03M | 94.26M | 149.56M | 101.75M |
| Capital expenditures | 0.94M | 0.37M | 0.34M | 5.75M | 2.86M |
| Change receivables | 4.85M | -18.50600M | - | - | - |
| Cash flows other operating | -12.22500M | -18.44700M | 3.94M | -8.36300M | -15.46200M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -131.53300M | -1367.29600M | 1533.73M | -64.23800M | -113.77400M |
| Change in working capital | 5.67M | -18.50600M | -39.72900M | 6.66M | 19.21M |
| Stock based compensation | 61.60M | 104.63M | 95.99M | 153.23M | 101.96M |
| Other non cash items | 4.35M | -10.59500M | -0.68800M | -10.64000M | -10.10700M |
| Free cash flow | -460.97300M | -378.55400M | 663.93M | -534.45700M | -263.53100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutic |
-0.44 3.30% | 12.89 | - | - | 113.37 | 1.53 | 33.87 | -0.5853 |
| NVO Novo Nordisk A/S |
2.55 2.08% | 125.26 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.76 3.07% | 126.26 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.64 1.43% | 399.92 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
2.35 2.71% | 89.17 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
215 First Street, Cambridge, MA, United States, 02142
| Name | Title | Year Born |
|---|---|---|
| Mr. Barry E. Greene | Pres, CEO & Director | 1963 |
| Ms. Kimi E. Iguchi CPA | CFO & Treasurer | 1962 |
| Dr. Albert J. Robichaud Ph.D. | Chief Scientific Officer | 1961 |
| Mr. Christopher Benecchi | Chief Bus. Officer | 1972 |
| Mr. Matt Lasmanis | Chief Technology & Innovation Officer | NA |
| Helen Rubinstein | Investor Relations Officer | NA |
| Ms. Anne Marie Cook Esq. | Sr. VP, Gen. Counsel & Sec. | 1962 |
| Ms. Erin E. Lanciani | Chief People & Experience Officer | 1969 |
| Dr. Amy Schacterle Ph.D. | Sr. VP of R&D Strategy and Bus. Management | NA |
| Dr. Jim Doherty Ph.D. | Chief Devel. Officer | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...